How to appeal a Horizon Blue Cross Blue Shield of New Jersey adult car-t cell therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Horizon Blue Cross Blue Shield of New Jersey-specific note: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).

What Horizon Blue Cross Blue Shield of New Jersey's policy requires for adult car-t cell therapy

Cited policy: BCBS Federal Employee Program Medical Policy — Brexucabtagene Autoleucel (Tecartus)

FDA-approved indication: r/r mantle cell lymphoma after >=2 prior lines including a BTK inhibitor (Jul 2020 ZUMA-2) OR adult (>=18) r/r B-cell precursor ALL (Oct 2021 ZUMA-3). Age >=18. ECOG 0-1. ANC >=1000, plt >=75K, LVEF >=50%, CrCl >=60, AST/ALT <2.5x ULN, total bili <1.5. No active CNS disease. Administered at FACT-accredited REMS-certified ATC. Bridging + Flu/Cy LD bundled.

How Horizon Blue Cross Blue Shield of New Jersey denies adult car-t cell therapy — and how to counter it

Where Horizon Blue Cross Blue Shield of New Jersey pushes back: 1) 'Try allo-HSCT first' for adult B-ALL; 2) Prior BTKi requirement strict-interpretation for MCL; 3) MRD+ disease deemed insufficient.

Counter-arguments that hold up: ZUMA-2 (Wang NEJM 2020) — Tecartus 87% ORR / 62% CR in r/r MCL post-BTKi → FDA Jul 24 2020. ZUMA-3 (Shah Lancet 2021) — Tecartus 71% CR/CRi in adult r/r B-ALL → FDA Oct 1 2021. NCCN ALL v2.2024 + NCCN B-cell Lymphomas v6.2024 list Tecartus as preferred regimen. Allo-HSCT carries 20-30% TRM vs Tecartus much lower TRM; many B-ALL patients ineligible for allo-HSCT due to age/comorbidity/no donor. ZUMA-3 entry criteria included MRD+ relapse; MRD+ qualifies as r/r disease per NCCN + IWG. Prior BTKi requirement met by any covalent or non-covalent BTKi exposure.

What Horizon Blue Cross Blue Shield of New Jersey typically denies for adult car-t cell therapy

Across Horizon Blue Cross Blue Shield of New Jersey's commercial and Medicare books, denials cluster around a small number of patterns. For adult car-t cell therapy, expect:

• OMNIA tier-1 vs tier-2 provider disputes
• Step therapy on biologics
• Behavioral health prior auth
• Out-of-state emergency reductions

Treatments most often denied in this category

These are the adult car-t cell therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Yescarta
• Kymriah
• Tecartus
• Breyanzi
• Carvykti
• Abecma

How to submit the appeal to Horizon Blue Cross Blue Shield of New Jersey

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Horizon Blue Cross Blue Shield of New Jersey cited in the denial.
3. File the appeal through Horizon Blue Cross Blue Shield of New Jersey's portal (members: https://www.horizonblue.com ; providers: https://www.horizonblue.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NJ, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Horizon Blue Cross Blue Shield of New Jersey's prior-authorization criteria by drug: Horizon Blue Cross Blue Shield of New Jersey PA criteria on ApprovalHelp.